コネチカット州における子宮内膜がんの臨床試験
コネチカット州内の拠点で、子宮内膜がんに関する20件の研究が参加者を募集しています。
コネチカット州内の都市
公式研究テキスト（英語）
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Yale Cancer Center, New Haven
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Hartford Hospital, Hartford
- Hartford HealthCare - Manchester, Manchester
- The Hospital of Central Connecticut, New Britain
被験者募集中第3相
18歳以上 · 女性 · 2026/10/02更新 · NCT07198074A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Yale Cancer Center, New Haven
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06172478Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, New Haven
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05867251A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
- Kivu Trial Site, New Have
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/24更新 · NCT07229313Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Yale University, Yale Cancer Center, New Haven
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Yale University School of Medicine ( Site 6009), New Haven
被験者募集中第3相
18歳以上 · 女性 · 2026/09/17更新 · NCT06952504A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- Yale University School of Medicine, New Haven
被験者募集中第3相
18歳以上 · 女性 · 2026/09/17更新 · NCT06340568Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- Norwalk Hospital, Danbury
- Hartford Hospital, Hartford
- Norwalk Hospital, Norwalk
被験者募集中第3相
18歳以上 · 女性 · 2026/09/09更新 · NCT07166094A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, New Haven
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07182149FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Yale University School of Medicine, New Haven
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05919264A Study of PHST001 in Advanced Solid Tumors
- Yale Cancer Center, New Haven
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/12更新 · NCT06840886Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
- Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford
被験者募集中観察研究
18歳以上 · 女性 · 2026/08/07更新 · NCT04291612Integrated Cancer Repository for Cancer Research
- Hartford HealthCare Cancer Institute at Manchester Medical Hospital, Manchester
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
- Smilow Cancer Hospital at Yale New Haven, New Haven
被験者募集中第2相
18歳〜100歳 · 女性 · 2026/06/26更新 · NCT03832361Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Yale University, Yale Cancer Center, New Haven
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/23更新 · NCT06993844A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Yale University, Yale Cancer Center, New Haven
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/03/27更新 · NCT06395519A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Yale Cancer Center, New Haven
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/11/04更新 · NCT05902988SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Hartford
- Massive Bio SYNERGY-AI site, Norwalk
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- Yale University, New Haven
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/02/13更新 · NCT05669430ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。